Brief: Genocea Presents Positive GEN-009 Clinical Results, Update On Gen-011 Program And New Inhibigentm Mechanism Of Action Data At SITC 2020

Genocea Biosciences

09/11/2020 14:22

Nov 9 (Reuters) - Genocea Biosciences Inc  GNCA.O :
    * GENOCEA PRESENTS POSITIVE GEN-009 CLINICAL RESULTS, UPDATE
ON
GEN-011 PROGRAM AND NEW INHIBIGENTM MECHANISM OF ACTION DATA AT
VIRTUAL SITC 2020
    * GENOCEA - NOVEL CLINICAL & DURABLE IMMUNE RESPONSE
PATTERNS
SUGGEST ADDITION OF GEN-009 MAY OFFER ADDITIVE CLINICAL BENEFIT
IN COMBINATION WITH PD-1-BASED THERAPIES
    * GENOCEA - ATLAS(TM)-IDENTIFIED INHIBIGENS DECREASE
ANTI-TUMOR T
CELL RESPONSES, CANNOT BE OVERCOME BY POWERFUL CHECKPOINT
BLOCKADE IMMUNOTHERAPY

Source text for Eikon:  ID:nGNXbqym8D 
Further company coverage:  GNCA.O 

 ((Reuters.Briefs@thomsonreuters.com;))